Key Highlights

  • Revenue was USD 200,000 against USD 75,000 estimated; the loss was USD 0.50 per share against USD 0.66.
  • Management reported its first pre-commercial product revenue, supplied on a paid per patient basis under a named patient Import pathway.
  • Net loss was USD 2.6 million against USD 2.9 million; R&D rose to USD 1.8 million from 1.1 million.
  • Cash was USD 7.5 million against USD 8.8 million at June 30; operating cash use was USD 1.3 million.

MiNK Therapeutics, Inc. (NASDAQ:INKT) reported third quarter 2026 Revenue of USD 200,000 against an estimate of USD 75,000. The loss was USD 0.50 per share against an estimate of negative USD 0.66, a beat of USD 0.16, and compared with a loss of USD 0.65 per share a year earlier. The company reported before the market open on November 11, 2026, and held its Earnings Call that day.

Management said it recognized its first pre-commercial product revenue, from its lead cell therapy candidate supplied on a paid per patient basis under a named patient import pathway, in collaboration with two partners and open in multiple countries outside the United States. Management said physician Demand produced patient access outside clinical trials.

Financial Results

Net loss for the quarter was USD 2.6 million, or USD 0.50 per share, compared with USD 2.9 million, or USD 0.65 per share, a year earlier. Research and Development expenses increased to USD 1.8 million from USD 1.1 million, which management attributed primarily to the timing of clinical trial activities, including a randomized Phase II study and translational analysis presented at major conferences in the quarter.

Cash used in operations was approximately USD 1.3 million in the quarter, down from approximately USD 2.1 million in the second quarter, the lowest quarter of the year. The company ended the quarter with USD 7.5 million in cash and cash equivalents, compared with USD 8.8 million at June 30.

Clinical Programs

Management said a randomized, placebo controlled Phase II study of its lead candidate plus standard of care in adults with acute lung injury and moderate to severe hypoxemic respiratory failure continued enrolling in Lviv, Ukraine during the quarter. It anticipates a comparative readout in 2027, reflecting the planned pace of enrollment.

An investigator sponsored Phase I study for graft versus host disease prevention, funded by a federal small Business grant and a clinical trial award, is moving toward first dosing. Management said its priorities include adding intensive care unit sites, sustaining enrollment, seeking FDA alignment on an adaptive Phase IIb and III design and pursuing supportive designations.

Items to Follow

Over the last five quarters, management said, it took the biology from refractory cancer into critical illness, started a randomized Phase IIb trial, began treating patients through paid access, earned federal validation for deployability and connected its oncology work to its fibrotic lung disease work.

The items to follow are enrollment in the randomized study, revenue from the named patient pathway, cash use and financing. Per share figures reflect the company's share count, which is small relative to its cash balance, so a USD 0.16 beat against the estimate corresponds to a modest dollar amount. The company's legal proceedings and related disclosures are flagged for human legal review.